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Abstract
Burosumab, a fully human monoclonal antibody to FGF23, is the only approved treatment for X-linked hypophosphatemia 
(XLH), a rare genetic disorder characterized by renal phosphate wasting and substantial cumulative musculoskeletal mor-
bidity. During an initial 24-week randomized, controlled trial, 134 adults with XLH received burosumab 1 mg/kg (n = 68) 
or placebo (n = 66) every 4 weeks. After 24 weeks, all subjects received open-label burosumab until week 48. This report 
describes the efficacy and safety of burosumab during the open-label treatment period. From weeks 24–48, serum phospho-
rus concentrations remained normal in 83.8% of participants who received burosumab throughout and were normalized in 
89.4% who received burosumab after placebo. By week 48, 63.1% of baseline fractures/pseudofractures healed fully with 
burosumab, compared with 35.2% with burosumab after placebo. In both groups, burosumab was associated with clinically 
significant and sustained improvement from baseline to week 48 in scores for patient-reported outcomes of stiffness, pain, 
physical function, and total distance walked in 6 min. Rates of adverse events were similar for burosumab and placebo. 
There were no fatal adverse events or treatment-related serious adverse events. Nephrocalcinosis scores did not change from 
baseline by more than one grade at either week 24 or 48. These data demonstrate that in participants with XLH, continued 
treatment with burosumab is well tolerated and leads to sustained correction of serum phosphorus levels, continued healing 
of fractures and pseudofractures, and sustained improvement in key musculoskeletal impairments.
Keywords Burosumab · FGF23 · X-linked hypophosphatemia (XLH) · Osteomalacia · Vitamin D
Introduction
X-linked hypophosphatemia (XLH) is a rare genetic dis-
order with substantial musculoskeletal and functional 
morbidities. XLH results from loss-of-function mutations 
in the PHEX gene (phosphate-regulating endopeptidase 
homologue, X-linked), causing increased circulating levels 
of fibroblast growth factor 23 (FGF23) [1, 2]. Excess FGF23 
impairs renal phosphate reabsorption and reduces serum 
1,25-dihydroxyvitamin D (1,25(OH)2D) [3], resulting in 
chronic hypophosphatemia, rickets, and osteomalacia. These 
abnormalities lead to bone deformities, fractures and pseu-
dofractures, and bone and joint pain. Over time, progressive 
enthesopathy results in pain, stiffness, and decreased mobil-
ity [4, 5]. A majority of adults with XLH also have frequent 
dental abscesses leading to tooth loss [5].
For decades, the standard of care for children and symp-
tomatic adults with XLH has been to administer oral phos-
phate supplements and active vitamin D metabolites or ana-
logs [6]. Management of comorbidities included treatment 
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of pain and joint stiffness and rigorous oral hygiene. How-
ever, none of these therapies addresses the underlying patho-
physiology of XLH. Furthermore, treatment with phosphate 
and vitamin D is often complicated by secondary hyperpar-
athyroidism and nephrocalcinosis [7–9].
Burosumab (previously KRN23) is a recombinant, fully 
human IgG1 monoclonal antibody that binds circulating 
FGF23 and inhibits its excess activity [10, 11]. Based on 
results from phase 1, 2, and 3 trials [10–13], in 2018 buro-
sumab became the first drug approved for the treatment of 
XLH in adults and children ≥ 1 year of age in the US and 
Canada and in children ≥ 1 year of age in the European 
Union. In the double-blind placebo-controlled period of a 
phase 3 trial in adults with XLH, administration of buro-
sumab every 4 weeks for 24 weeks was associated with 
rapid normalization of serum phosphorus concentration, an 
approximately 17-fold greater likelihood of fracture healing, 
and a significant reduction in stiffness compared with pla-
cebo [13]. Reductions in pain and physical function impair-
ment were also observed from baseline to week 24 in the 
burosumab group.
In that trial, after completion of the 24-week, placebo-
controlled period, participants transitioned to a 24-week 
open-label burosumab treatment continuation period, in 
which efficacy and safety assessments were continued, fol-
lowed by an ongoing open-label extension period for up to 
two additional years. The present report summarizes the 
efficacy of burosumab administration in each group during 
the treatment continuation period and analyzes all available 
safety data throughout the duration of burosumab exposure, 
which ranged from 24 to 74 weeks.
Methods
Study Design
Complete methods have been published for the initial 
24-week randomized, double-blind, placebo-controlled 
period of this phase 3 trial [13], which was conducted at 
25 centers in the US, UK, Japan, France, South Korea, Ire-
land, and Italy. Eligible participants were randomized 1:1 
to receive burosumab or placebo in a double-blind fashion 
administered subcutaneously every 4 weeks for 24 weeks. 
Thereafter, participants from both groups entered a treat-
ment continuation period during which all participants 
received open-label burosumab at 1 mg/kg every 4 weeks.
Participants
Key inclusion criteria were age 18 to 65 years and a diag-
nosis of XLH supported by a confirmed PHEX mutation 
in the participant or related family member. PHEX muta-
tion analysis was performed by a central laboratory using 
guidelines set forth by the American College of Medi-
cal Genetics [14], in silico predictor models, and publicly 
available databases to determine pathogenicity. Clinical 
and laboratory data at screening were consistent with a 
diagnosis of XLH: serum phosphorus concentration below 
the lower limit of normal (LLN, 2.5 mg/dL [0.81 mmol/L]) 
and tubular maximum for phosphate reabsorption per 
glomerular filtration rate (TmP/GFR) below 2.5 mg/dL 
(0.81 mmol/L), as measured at a local laboratory. A Brief 
Pain Inventory (BPI) Worst Pain score of ≥ 4 on a scale 
from 0 to 10 at screening was also required. Key exclu-
sion criteria were corrected serum calcium ≥ 10.8 mg/
dL (2.7  mmol/L), serum intact parathyroid hormone 
(iPTH) ≥ 2.5-fold the upper limit of normal, use of a med-
ication to suppress parathyroid hormone within 60 days 
before screening, or a recent history (≤ 6 months) of trau-
matic fracture or orthopedic surgery. Potential participants 
taking oral phosphate and active vitamin D metabolites or 
analogs were screened, and if found eligible, enrolled after 
a 2-week washout period.
The study was designed, conducted, recorded, and 
reported in accordance with the principles established 
by the WorldMedical Association Declaration of Hel-
sinki Ethical Principles for Medical Research Involving 
Human Subjects. The Institutional Review Board or Eth-
ics Committee for each site approved the study protocol. 
Investigators obtained written informed consent from 
each study participant. The clinical trial was registered as 
NCT02526160/EudraCT2014-005529-11.
Treatments
From baseline to week 24, participants received either 
burosumab 1 mg/kg (rounded to the nearest 10 mg, maxi-
mum 90 mg) or matching placebo, administered subcu-
taneously every 4 weeks. After week 24, all participants 
received burosumab. Through week 48, trained healthcare 
providers administered all study injections. Although 
treatment in weeks 24–48 was not blinded, participants 
and study site staff remained blinded to the original treat-
ment assignment. In this report, the treatment groups are 
described as “burosumab–burosumab” or “placebo–buro-
sumab” to describe the sequence of treatments received 
before and after week 24. If the serum phosphorus concen-
tration was greater than 5.0 mg/dL (1.61 mmol/L) at any 
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time or if two sequential serum phosphorus concentrations 
were between 4.5 and 5.0 mg/dL, the dose of burosumab 
was decreased by half; subsequent dose adjustments were 
determined by the investigator and medical monitor.
Outcomes
Efficacy assessments were fasting measurements of serum 
phosphorus (weeks 0, 1, 2, 4, 6, 10, 12, 14, 18, 20, 21, 22, 
24, 26, 28, 34, 36, 46, and 48), serum 1,25(OH)2D (weeks 
0, 1, 2, 4, 20, 21, 22, 24, 46, and 48), and TmP/GFR (weeks 
0, 2, 4, 12, 22, 24, and 48). Estimated GFR was calculated 
by using the Chronic Kidney Disease Epidemiology Col-
laboration equation [15]. Biochemical markers of bone 
remodeling were serum procollagen type 1 N-propeptide 
(PINP), carboxy-terminal cross-linked telopeptide of type 
I collagen (CTX), and bone-specific alkaline phosphatase 
(every 12 weeks). Patient-reported outcomes were assessed 
using the short-form BPI questionnaire [16] and the West-
ern Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) questionnaire [17] (every 12 weeks). Efficacy 
endpoints for patient-reported outcomes were BPI Worst 
Pain, scored from 0 (no pain) to 10 (worst pain), and the nor-
malized WOMAC scores for stiffness and physical function, 
scored from 0 (best health state) to 100 (worst health state). 
Functional exercise capacity was measured as total distance 
walked during the 6-min walk test [18] (every 12 weeks). 
Active, unhealed fractures (visible fracture line extending 
across the entire cortex) and pseudofractures (visible frac-
ture line involving a portion of the cortex) were identified at 
baseline by a complete radiographic skeletal survey; radio-
graphs at baseline fracture sites were repeated at 12-week 
intervals to assess healing. Partial healing was defined as a 
fracture line that was partially visible and partially obscured 
by callous formation; full healing was defined as focal cor-
tical thickening/contour deformity with no evidence of an 
active fracture line. Safety measurements included adverse 
events and serious adverse events (at any time), renal ultra-
sound nephrocalcinosis grades, fasting serum calcium (same 
schedule as phosphorus) and plasma iPTH (same schedule 
as 1,25(OH)2D), and 24-h urine calcium excretion (every 
12 weeks). All postbaseline serum and plasma concentra-
tions were determined by a central laboratory. Ultrasono-
graphic findings of nephrocalcinosis were graded on a 
5-point scale, as follows: 0 = normal, 1 = faint hyperecho-
genic rim around the medullary pyramids, 2 = more intense 
echogenic rim with echoes faintly filling the entire pyramid, 
3 = uniformly intense echoes throughout the pyramid, and 
4 = stone formation: solitary focus of echoes at the tip of 
the pyramid [8, 19].
Statistical analysis
The primary and key secondary study endpoints compared 
the efficacy of burosumab and placebo through week 24; the 
analytical methods were described [13] (also see Supple-
mental Methods). Secondary and exploratory endpoints for 
the treatment continuation period included the changes from 
baseline through week 48 for each efficacy measurement, 
and the number and percentage of pseudofractures/fractures 
identified at baseline that were fully or partially healed at 
weeks 12, 24, 36, and 48. Safety endpoints included inci-
dences and exposure-adjusted incidences for adverse events 
throughout the duration of burosumab exposure, which 
ranged from 24 to 74 weeks.
Descriptive summaries for efficacy and safety results were 
provided by treatment group. For selected endpoints, the 
least squares (LS) mean, standard error (SE), and 95% con-
fidence interval (CI) for the change from baseline to week 
48 were determined for each treatment group using general-
ized estimating equation (GEE) repeated-measures analysis, 
including treatment group, actual stratification factor, visit, 
and interaction of group-by-visit as fixed factors, adjusted 
for baseline measurement. Similar GEE models were used 
in the placebo–burosumab group to examine the LS mean 
change from weeks 24 to 48 for BPI Worst Pain, WOMAC 
physical function and stiffness, and total distance walked in 
6 min. Probabilities of full healing of fractures/pseudofrac-
tures in each group at week 48 were estimated using a gen-
eralized linear mixed model for binomial distribution that 
included treatment group, visit, interaction of group-by-visit, 
and fracture type as fixed factors, accounting for nesting 
of fractures within participants. Two-sided hypothesis tests 
were performed at the 5% level of significance.
Results
Participants and Treatment
One hundred thirty-four participants were enrolled and 
randomized 1:1 to receive burosumab (n = 68) or placebo 
(n = 66). One-hundred thirty-three participants completed 
the 24-week placebo-controlled period and entered the treat-
ment continuation period, and one participant in the buro-
sumab–burosumab group withdrew consent after approxi-
mately 6 months (Fig. 1). Overall, 126 (94.0%) participants 
completed week 48 of the treatment continuation period and 
entered the open-label extension. Seven participants discon-
tinued between weeks 24 and 48; one withdrew consent, 
one became pregnant, and five either chose to discontinue 
or did not re-consent after the study protocol was amended 
in July and September 2016. No participant discontinued 
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the study due to an adverse event. All participants (n = 134) 
were included in the efficacy and safety analyses.
Baseline demographic, clinical, and radiographic charac-
teristics were similar between the treatment groups (Table 1). 
The mean age of participants was 40 years and 87 (64.9%) 
were female. Seventy (52.2%) participants had a total of 156 
fractures (n = 27) or pseudofractures (n = 129), predomi-
nately in the weight-bearing bones of the lower extremi-
ties. Osteoarthritis was present in 63.4% of participants, and 
enthesopathy was present in nearly all participants (99.3%). 
We found no association between the presence of fractures/
pseudofractures and participant age, sex, body mass index, 
serum phosphorus concentration, or bone turnover markers 
at baseline. Patient-reported outcome scores (mean ± SD) at 
baseline were as follows: WOMAC stiffness, 63.1 ± 20.50; 
WOMAC physical function, 47.4 ± 20.02; and BPI Worst 
Pain, 6.7 ± 1.37. At screening, all participants reported BPI 
Worst Pain score of 4 (moderate pain) or greater, per the 
study eligibility criteria, and most (71.6%) reported BPI 
Worst Pain score of > 6.0 (severe pain) at baseline. For the 
entire group at baseline, severe or extreme stiffness (a score 
of 3 or 4, respectively; scale 0–4) upon awakening, and 
later in the day, was reported by 79 (59.0%) and 68 (50.7%) 
participants, respectively. Stiffness scores did not associate 
with age, sex, presence of enthesopathy or osteoarthritis, or 
serum phosphorus concentration at baseline.
Before enrolling in the current study, most participants 
(90.3%) had received oral phosphate or vitamin D metabo-
lites/analogs and the majority (69.4%) had first received 
these therapies in childhood (Online Resource 1). The 
mean duration of therapy was 16.5 years for phosphate 
and 18.2 years for active vitamin D. At baseline, 67.9% of 
participants were using pain medication; 22.4% used an 
opioid.
Pharmacodynamic Effects of Burosumab
Burosumab‑Burosumab Group
In participants who received burosumab throughout the 
study, mean serum phosphorus concentrations increased to 
values above the LLN at week 1 and remained at or above 
this value throughout, when measured both at the mid-
point (Fig. 2a) and the end (Fig. 2b) of each 4-week dos-
ing interval. Mean phosphorus concentrations (averaged 
across the midpoints) were above the LLN in 94.1% of par-
ticipants between weeks 0 and 24, and in 83.8% between 
weeks 24 and 48 (Online Resource 2). The LS mean (95% 
CI) increase in phosphorus concentrations from baseline to 
week 46 (midpoint of dosing interval) was 0.9 mg/dL (0.7, 
1.0) and from baseline to week 48 (end of dosing interval) 
was 0.4 mg/dL (0.2, 0.5). The increase was attributed to the 
increase in renal phosphate reabsorption, as reflected by the 
LS mean (95% CI) increase from baseline to week 48 in 
TmP/GFR (0.5 mg/dL [0.3, 0.7]; Fig. 2c). LS mean (95% 
CI) increases from baseline to week 48 were also seen for 
serum 1,25(OH)2D (7.1 pg/mL [1.5, 12.8]; Fig. 2d), PINP 
(35.7 ng/mL [17.5, 53.9]; Fig. 2e), CTX (127.1 pg/mL [36.7, 
217.5]; Fig. 2f), and BALP (1.2 µg/L [− 2.3, 4.8]; Fig. 2g). 
For each laboratory value, the largest increase was seen at 
the first post-baseline measurement, with subsequent attenu-
ation and stabilization of the effect of burosumab over the 
course of the study.
Total (N=134)
Randomization Placebo-burosumab (n=66) Burosumab-burosumab (n=68)
Placebo-controlled period
(weeks 0-24)
Entered (n=66)
Discontinued (n=0)
Completed (n=66)
Entered (n=68)
Discontinued (n=1)
- Withdrew consent (n=1)
Completed (n=67)
Treatment continuation period
(weeks 24-48)
Entered (n=66)
Discontinued (n=3)
- Other reason (n=3)
Completed (n=63)
Entered (n=67)
Discontinued (n=4)
- Withdrew consent (n=1)
- Other reason (n=3)
Completed (n=63)
Fig. 1  Disposition of study participants
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Table 1  Baseline demographic, 
clinical, and radiographic 
characteristics
Data are mean ± SD or n (%)
1,25(OH)2D 1,25dihydroxyvitamin D, BPI Brief Pain Inventory, iPTH intact parathyroid hormone, 
Placebo–buro-
sumab (n = 66)
Burosumab–buro-
sumab (n = 68)
Total (n = 134)
Age (years)
 Mean ± SD 38.7 ± 12.8 41.3 ± 11.6 40.0 ± 12.2
 Range 18.5–65.5 20.0–63.4 18.5–65.5
Female, n (%) 43 (65.2) 44 (64.7) 87 (64.9)
Race, n (%)
 White 53 (80.3) 55 (80.9) 108 (80.6)
 Asian 9 (13.6) 12 (17.6) 21 (15.7)
 Black 3 (4.5) 0 3 (2.2)
 Other 1 (1.5) 1 (1.5) 2 (1.5)
Geographic region, n (%)
 North America/Europe 58 (87.9) 58 (85.3) 116 (86.6)
 Japan 5 (7.6) 6 (8.8) 11 (8.2)
 South Korea 3 (4.5) 4 (5.9) 7 (5.2)
Heighta, mean ± SD
 cm 153 ± 11.8 152 ± 9.5 152 ± 10.7
 Z-scoreb − 2.3 ± 1.3 − 2.3 ± 1.2 − 2.3 ± 1.3
 Percentile 7.2 ± 12.1 6.4 ± 12.9 6.8 ± 12.5
Body mass  indexa (kg/m2), mean ± SD 30.6 ± 7.8 30.0 ± 7.5 30.3 ± 7.6
PHEX mutation, n (%)
 Pathogenic 50 (75.8) 45 (66.2) 95 (70.9)
 Likely pathogenic 7 (10.6) 8 (11.8) 15 (11.2)
 Variant of uncertain s ignificance 8 (12.1) 9 (13.2) 17 (12.7)
No mutation 1 (1.5) 6 (8.8) 7 (5.2)
WOMAC  stiffnessc, mean ± SD 61.4 ± 20.8 64.7 ± 20.3 63.1 ± 20.5
WOMAC physical  functionc, mean ± SD 43.9 ± 19.9 50.8 ± 19.7 47.4 ± 20.0
BPI Worst Pain, mean ± SD 6.5 ± 1.4 6.8 ± 1.3 6.7 ± 1.4
BPI Worst Pain > 6.0, n (%) 43 (65.2) 53 (77.9) 96 (71.6)
Any pain medication at baseline, n (%) 44 (66.7) 47 (69.1) 91 (67.9)
Any opioid at baseline, n (%) 13 (19.7) 17 (25.0) 30 (22.4)
Medical  historyd, n (%)
 Orthopedic surgery 47 (71.2) 45 (66.2) 92 (68.7)
 Osteoarthritis 38 (57.6) 47 (69.1) 85 (63.4)
TmP/GFR (mg/dL)e, mean ± SD 1.6 ± 0.37 1.7 ± 0.40 1.6 ± 0.39
Serum phosphorus (mg/dL)e, mean ± SD 1.9 ± 0.32 2.0 ± 0.30 2.0 ± 0.31
Serum 1,25(OH)2D (pg/mL)e, mean ± SD 33.5 ± 15.6 32.4 ± 13.0 33.0 ± 14.3
Serum calcium (mg/dL)e, mean ± SD 9.1 ± 0.41 9.2 ± 0.49 9.2 ± 0.45
Plasma iPTH (pg/mL)e, mean ± SD 95.2 ± 38.8 98.9 ± 60.8 97.0 ± 50.9
Enthesopathy on X-ray, n (%) 65 (98.5) 68 (100.0) 133 (99.3)
Nephrocalcinosis  gradef, n (%)
 0 27 (40.9) 34 (50.0) 61 (45.5)
 1 32 (48.5) 23 (33.8) 55 (41.0)
 2 7 (10.6) 9 (13.2) 16 (11.9)
 3 0 2 (2.9) 2 (1.5)
Unhealed fracture/pseudofracture at baseline
n (%) of participants 38 (57.6) 32 (47.1) 70 (52.2)
No. of fractures/pseudofractures 91 65 156
 Fractures 13 14 27
 Pseudofractures 78 51 129
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Placebo–Burosumab Group
During administration of placebo from weeks 0 to 24, lit-
tle or no effect on serum phosphorus, TmP/GFR, or bone 
remodeling markers was observed (Fig. 2). After partici-
pants initiated burosumab at week 24, serum phosphorus 
concentrations promptly increased and remained at or 
above the LLN, with LS mean (95% CI) increases from 
baseline seen through week 46 (midpoint of dosing inter-
val; 1.0 mg/dL [0.8, 1.1]; Fig. 2a) and week 48 (end of 
dosing interval; 0.4 mg/dL [0.2, 0.6]; Fig. 2b). Mean phos-
phorus concentrations (measured at midpoints) were above 
the LLN in 7.6% of participants during administration of 
placebo (weeks 0–24), and in 89.4% of participants dur-
ing administration of burosumab (weeks 24–48) (Online 
Resource 2). LS mean (95% CI) increases from baseline to 
week 48 were also seen for 1,25(OH)2D (10.2 pg/mL [4.7, 
15.7]; Fig. 2c), TmP/GFR (0.6 mg/dL [0.4, 0.8]; Fig. 2d), 
PINP (76.9 ng/mL [54.9, 98.9]; Fig. 2e), CTX (295.9 pg/
mL [200.8, 391.1]; Fig. 2f), and BALP (6.7 µg/L [2.6, 
10.7]; Fig. 2g) after initiation of burosumab. As in the 
other treatment group, the largest increase for each labora-
tory value was seen at the first assessment after initiation 
of burosumab at week 24.
Fracture/Pseudofracture Healing
Burosumab–Burosumab Group
At baseline in the burosumab–burosumab group, 32 (47.1%) 
participants had a total of 65 unhealed fractures (n = 14) or 
pseudofractures (n = 51). The proportion of fractures fully 
healed in this group at weeks 12, 24, 36, and 48 was 20.0, 
43.1, 50.8, and 63.1%, respectively (Fig. 3). Probabilities of 
full healing estimated from a generalized linear mixed model 
are provided in Online Resource 2. At week 48, 80.0% of 
baseline fractures and pseudofractures were either fully 
(63.1%) or partially (16.9%) healed; 9.2% were unhealed and 
10.8% were not evaluable because follow-up X-rays were not 
obtained. Full and partial healing by anatomic location are 
summarized in Online Resource 3.
Placebo–Burosumab Group
At baseline in the placebo–burosumab group, 38 (57.6%) 
participants had a total of 91 unhealed fractures (n = 13) or 
pseudofractures (n = 78). During placebo administration, 
only 7.7% of fractures and pseudofractures were fully healed 
at weeks 12 and 24 (Fig. 3). After transition to burosumab, 
23.1% and 35.2% of fractures and pseudofractures were fully 
healed at weeks 36 and 48, respectively, mirroring the rates 
of healing at weeks 12 and 24 in the burosumab–burosumab 
group. Probabilities of full healing estimated from a gener-
alized linear mixed model are provided in Online Resource 
2. At week 48, 74.8% of baseline fractures and pseudofrac-
tures were either fully (35.2%) or partially (39.6%) healed; 
12.1% were unhealed and 13.2% were not evaluable because 
follow-up X-rays were not obtained. Full and partial healing 
by anatomic location are summarized in Online Resource 3.
Patient‑Reported Outcomes and Functional Exercise 
Capacity
Burosumab–Burosumab Group
Burosumab for 48 weeks was associated with a sustained 
improvement in scores for the patient-reported outcomes 
of stiffness, pain, and physical function, and improvement 
in total distance walked in 6 min (Fig. 4, Online Resource 
2). The improvements from baseline to week 48 were sig-
nificant (p < 0.001) for WOMAC stiffness (LS mean ± SE: 
− 16.03 ± 3.315) and WOMAC physical function impair-
ment (− 7.76 ± 2.146), where lower scores represent better 
health. Severe or extreme stiffness upon waking (WOMAC 
Question 6) was reported by 63% of participants at baseline 
and decreased to 45% at week 24 and only 27% at week 
48. Severe or extreme stiffness later in the day (WOMAC 
TmP/GFR tubular maximum for phosphate reabsorption per glomerular filtration rate
a Height and body mass index were not recorded at baseline for one participant in each group
b Z-score adjusted for sex
c On a normalized scale from 0 (best health state) to 100 (worst health state)
d Based on medical history at screening
e Normal range: phosphorus, 2.5–4.5 mg/dL; 1,25(OH)2D, 18–72 pg/mL; calcium, 8.6–10.2 mg/dL; iPTH, 
14–72 pg/mL
f Graded on a 5-point scale where 0 = normal, 1 = faint hyperechogenic rim around the medullary pyramids, 
2 = more intense echogenic rim with echoes faintly filling the entire pyramid, 3 = uniformly intense echoes 
throughout the pyramid, 4 = stone formation: solitary focus of echoes at the tip of the pyramid [8, 19]
Table 1  (continued)
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Question 7) was reported by 54% of participants at base-
line and decreased to 31% at week 24 and 26% at week 
48 (Online Resource 4). Improvements from baseline to 
week 48 were also observed for BPI Worst Pain score (LS 
mean ± SE: − 1.09 ± 0.216) and total distance walked in 
6 min (30.5 ± 6.93 m) (both p < 0.001) (Fig. 4). Opioids were 
used by 25.0% of participants at baseline, 23.5% at week 
24, and 20.6% at week 48; this change was not statistically 
significant.
Placebo–Burosumab Group
Participants receiving placebo reported modest improve-
ments in pain but no improvement in scores for stiffness 
and physical function at week 24 (Fig. 4). After transition 
to burosumab, participants reported significant reductions 
from weeks 24 to 48 for WOMAC stiffness (LS mean ± SE: 
− 15.82 ± 2.795) and WOMAC physical function impair-
ment (LS mean ± SE: − 8.18 ± 1.716; both p < 0.0001), 
where lower scores represent better health (Online Resource 
2). Specifically, severe or extreme stiffness upon waking 
(WOMAC Question 6) was reported by 54% of participants 
at baseline and week 24 but fell to 29% at week 48. Severe 
or extreme stiffness later in the day (WOMAC Question 
7) was reported by 47% of participants at baseline, 42% at 
week 24, but by only 20% at week 48 (Online Resource 4). 
Participants also reported that BPI Worst Pain decreased 
significantly from week 24 to week 48 (LS mean ± SE: 
− 1.18 ± 0.216; p < 0.001; Fig. 4). In the placebo–buro-
sumab group, opioids were used by 19.7% of participants 
at baseline, 21.2% at week 24, and 17.5% at week 48; these 
changes were not statistically significant. Additionally, 
scores for functional exercise capacity (total distance walked 
in 6 min), which did not change from baseline to week 24 in 
this group, increased from weeks 24 to 48 (LS mean ± SE: 
23.0 ± 5.62 m, p < 0.001; Fig. 4). Of note, participants and 
study staff remained blinded to the initial treatment assign-
ment through week 48.
Safety
Safety data were obtained throughout the period of buro-
sumab exposure, including the extension period. The mean 
duration of exposure in the burosumab–burosumab group 
was 404 days (range 167–521) and in the placebo–buro-
sumab group, 242 days (range 165–403). The incidence, 
nature, and severity of adverse events were similar between 
treatment groups (Table 2). There were no treatment-related 
serious adverse events, study or treatment discontinuations 
due to an adverse event, or fatal adverse events. Exposure-
adjusted rates of individual adverse events that were reported 
during exposure to burosumab were similar to those reported 
during exposure to placebo (Online Table 5).
Nephrocalcinosis grades of 1–3 were observed at baseline 
in 73 (54.5%) participants. At week 24, nephrocalcinosis 
increased by one grade in 11 (16.2%) participants receiving 
burosumab and 12 (18.2%) participants receiving placebo; 
by week 48, nephrocalcinosis grades decreased to baseline 
levels in the majority of these participants (6 of 11 [54.5%] 
in the burosumab–burosumab group and 8 of 12 [66.7%] in 
the placebo–burosumab group). Nephrocalcinosis decreased 
by one grade in 8 (11.8%) participants receiving burosumab 
(4 at week 24 and 4 at week 48) and in 5 (7.6%) participants 
in the placebo–burosumab group (4 at week 24 and 1 at 
week 48). Nephrocalcinosis did not change from baseline 
by more than one grade in any participant, and changes in 
nephrocalcinosis grade were not associated with changes 
in urine calcium excretion, serum iPTH, or estimated GFR.
Due to increases in serum phosphorus concentration 
above the target range, the dose of burosumab was decreased 
in 5 (7.4%) participants in the burosumab–burosumab group 
(during weeks 0–24) and 4 (6.1%) participants in the pla-
cebo–burosumab group (during weeks 24–48); phosphorus 
levels subsequently normalized in each participant. One 
of these participants subsequently received burosumab at 
the original dose of 1 mg/kg. Mean serum calcium, plasma 
iPTH, and urine calcium excretion did not increase with 
burosumab administration (Fig. 5).
Two female participants discontinued the study due to 
pregnancy; one during the treatment continuation period, 
as described above, and one after completing the treat-
ment continuation period during the open-label extension. 
Each woman carried the pregnancy to term and delivered a 
healthy infant with no complications.
Discussion
In the present 48-week, phase 3 trial of burosumab, adults 
with XLH participated in a 24-week randomized, double-
blind, placebo-controlled period to evaluate the efficacy and 
safety of burosumab and a subsequent 24-week continua-
tion period in which all participants received burosumab 
to confirm efficacy and safety with longer-term use. The 
results demonstrate that with continued exposure to buro-
sumab, phosphorus homeostasis was maintained, the pro-
portion of fully healed fractures and pseudofractures pro-
gressively increased, and pain, stiffness, physical function, 
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and functional exercise capacity scores improved. Despite 
long-standing physical impairments from a lifetime of XLH, 
participants experienced clinically meaningful benefits that 
began shortly after burosumab was initiated and persisted 
with continued administration, with an overall positive 
benefit-risk profile through at least 48 weeks of treatment.
In the initial 24 weeks, administration of burosumab 
resulted in significant improvements in serum phosphorus, 
TmP/GFR, 1,25(OH)2D, bone biomarkers, fracture healing, 
and patient-reported outcomes, compared with administra-
tion of placebo [13]. In the subsequent 24 weeks when all 
participants received burosumab, mean serum phosphorus 
concentration, measured at the midpoints of dose intervals, 
was within the normal range in 84% and 89% of partici-
pants in the burosumab–burosumab and placebo–burosumab 
groups, respectively, demonstrating sustained efficacy of 
burosumab in normalizing phosphorus homeostasis. In 
each group, the maximum effects on serum phosphorus and 
1,25(OH)2D were observed after the first dose of burosumab, 
with a small attenuation in the drug’s effect with subsequent 
doses. After three or four doses, serum phosphorus remained 
stable and within the normal range, which is the therapeu-
tic target for burosumab. The relative long-term stabilityof 
serum phosphorus and 1,25(OH)2D suggests thatdesensitiza-
tion to the effects of burosumab does not occur over time.
In patients with XLH, chronic osteomalacia can lead to 
fractures and pseudofractures, which were observed in half 
of the study participants at baseline, most commonly in the 
lower extremities. The proportion of fractures and pseu-
dofractures that healed was greater over time in the group 
receiving burosumab, with 80% achieving partial or com-
plete healing by week48. For the group initiating burosumab 
at week 24, healing of fractures and pseudofractures at week 
48 replicated the healing at week 24 in the group receiv-
ing burosumab from the outset. Healing of fractures and 
pseudofractures with burosumab is presumed to reflect an 
improvement in bone mineralization and remodeling. This 
formulation is supported by the initial increase in markers 
of bone formation (PINP, BALP) and resorption (CTX) after 
initiating burosumab in each treatment group, followed by 
a gradual attenuation of the increase in bone biomarkers 
over time.
All participants reported at least moderate pain, which 
was a criterion for enrollment, with a large majority 
reporting severe pain. A majority of participants also 
reported severe or extreme stiffness. Mean scores for stiff-
ness and physical function were similar to or worse than in 
patients with severe osteoarthritis [20]. After initiation of 
burosumab, scores for pain, stiffness, and physical func-
tion improved significantly from baseline in both treatment 
groups. After 24 weeks of burosumab, the magnitude of 
improvement was almost identical in participants initi-
ating burosumab at week 0 and in those transitioning to 
burosumab at week 24. By week 48, fewer than 30% of 
participants in either group had residual severe or extreme 
stiffness. Functional exercise capacity, as measured by the 
total distance walked in 6 min, also improved after initia-
tion of burosumab in each group. The consistent effects 
on patient-reported outcomes during the first 24 weeks 
of burosumab and the sustained effects through week 48 
are notable and provide further evidence of the benefits 
of burosumab in XLH patients previously treated with 
Fig. 2  Effect of burosumab on concentrations of a serum phos-
phorus measured at the midpoint of the dosing interval (1–2  weeks 
after a dose), b serum phosphorus measured at the end of the dos-
ing interval (4  weeks after a dose), c TmP/GFR (tubular maximum 
for phosphate reabsorption per glomerular filtration rate) (TmP/GFR), 
d serum 1,25-dihydroxyvitamin D [1,25(OH)2D], e procollagen type 
1 N-propeptide (PINP), f carboxy-terminal cross-linked telopeptide 
of type I collagen (CTX), and g bone-specific alkaline phosphatase 
(BALP). Participants received either burosumab or placebo in a dou-
ble-blind fashion every 4 weeks for the first 24 weeks; all participants 
then received burosumab every 4 weeks beginning at week 24 while 
remaining blinded to their previous treatment assignment. Arrows 
indicate administration of study drug (burosumab or placebo). Blood 
and urine were collected after a minimum overnight fasting time of 
8  h and prior to study drug administration. Data are expressed as 
mean ± standard error. The dashed lines are the lower and upper lim-
its of normal. Conversion factors: phosphorus and TmP/GFR, 1 mg/
dL = 0.32 mmol/L; 1,25(OH)2D, 1 pg/mL = 2.6 pmol/L
◂
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Fig. 3  Proportion of baseline fractures and pseudofractures fully 
healed. Participants received either burosumab or placebo in a dou-
ble-blind fashion every 4 weeks for the first 24 weeks; all participants 
then received burosumab every 4 weeks beginning at week 24 while 
remaining blinded to their previous treatment assignment
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conventional therapy. These improvements were achieved 
despite long-standing skeletal abnormalities that can cause 
pain that is not lessened by healing of osteomalacia or 
fractures. A majority of participants had osteoarthritis 
at baseline, and almost all had enthesopathy on baseline 
radiographs. It remains to be seen whether normalization 
of serum phosphorus with burosumab affects the incidence 
or course of enthesopathy. Together, these findings sug-
gest that treatment with burosumab may well be associated 
with continued improvement in the substantial burden of 
disease that accumulates over a lifetime, improvements 
that are clinically meaningful to adults with XLH.
The present analysis identified no new safety concerns 
relative to those previously observed [13]. Adverse events 
observed during administration of burosumab were similar 
to those during administration of placebo, and the adverse 
event profile did not appear to change with an additional 
24 weeks of burosumab. Most adverse events were mild 
to moderate in severity, and no participant stopped buro-
sumab or withdrew from the study due to an adverse event. 
No treatment-related serious adverse events, deaths, or 
life-threatening adverse events were observed. Elevation 
a b
c d
Fig. 4  Effect of burosumab on patient-reported outcomes and func-
tion, including a Western Ontario McMaster Universities Osteoar-
thritis Index (WOMAC) stiffness, b WOMAC physical function, c 
Brief Pain Inventory (BPI) Worst Pain, and d total distance walked 
in 6  min. Participants received either burosumab or placebo in a 
double-blind fashion every 4 weeks for the first 24 weeks; all partici-
pants then received burosumab every 4 weeks beginning at week 24 
while remaining blinded to their previous treatment assignment. Data 
are expressed as mean ± standard error. *p < 0.001 for least squares 
mean change from baseline to week 48 (burosumab–burosumab), 
**p < 0.001 for least squares mean change from weeks 24 to 48 (pla-
cebo–burosumab)
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in serum phosphorus concentration, observed in 7% of par-
ticipants during burosumab treatment, was without clinical 
manifestations and resolved after dose reduction. Nephro-
calcinosis and hyperparathyroidism are known complica-
tions associated with oral phosphate and active vitamin D 
[6, 7, 9, 21]. No participant had more than a single grade 
increase or decrease in nephrocalcinosis score. Serum cal-
cium and PTH concentrations and urine calcium excretion 
were unchanged with burosumab.
These data demonstrate that in adults with XLH, 
treatment with burosumab is associated with significant 
efficacy and an acceptable safety profile through 48 weeks. 
Sustained normalization of serum phosphorus concentra-
tion leads to healing of fractures and pseudofractures, 
strongly suggesting that bone mineralization and remod-
eling also improve with continued burosumab treatment. 
Use of the novel agent burosumab to normalize phospho-
rus homeostasis in adults with XLH results in sustained 
improvement in the important clinical parameters of stiff-
ness, pain, and functional exercise capacity.
Table 2  Summary of safety through data cutoff date
TEAE treatment-emergent adverse event
a Exposure-adjusted event incidence is defined as the total number of occurrences of the event divided by the total observed time for adverse 
events
b TEAEs classified by the investigator as possibly related, probably related, or definitely related
n (%) [exposure-adjusted event incidence/year]a
Double-blind Treatment Any Exposure to Burosumab
Placebo (n = 66) Burosumab (n = 68) Placebo- Burosumab 
(n = 66)
Burosumab- 
Burosumab 
(n = 68)
Weeks 0–24 Weeks 0–24 Weeks 24–cutoff Weeks 0–cutoff
Any TEAE 61 (92.4) [9.29] 64 (94.1) [9.93] 63 (95.5) [9.27] 68 (100.0) [9.68]
Related  TEAEb 26 (39.4) [1.65] 30 (44.1) [2.30] 32 (48.5) [1.60] 42 (61.8) [1.96]
Serious TEAE 2 (3.0) [0.07] 2 (2.9) [0.06] 8 (12.1) [0.18] 7 (10.3) [0.12]
Grade 3 or 4 TEAE 9 (13.6) [0.49] 8 (11.8) [0.35] 14 (21.2) [0.53] 15 (22.1) [0.30]
Related serious  TEAEb 0 0 0 0
TEAE led to study discontinuation 0 0 0 0
TEAEs led to treatment discontinuation 0 0 0 0
TEAEs leading to death 0 0 0 0
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